Ask AI
ProCE Banner Series

Team Strategies for Overcoming Challenges to Guideline-Concordant Care of High-Risk HR-Positive/HER2-Negative Early Breast Cancer

In this multidisciplinary workshop, experts will provide practical insights into optimizing care for patients with high-risk HR-positive/HER2-negative early breast cancer. Topics covered include identifying patients eligible for adjuvant CDK4/6 inhibitors, aligning treatment decisions with NCCN Guidelines and pivotal trial data, and personalizing therapy based on clinical and patient-specific factors

Complete the evaluation for this event: https://education.nccn.org/breast-series 

Who Should Attend

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR-positive/HER2-negative early breast cancer.

Topics

Breast Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge and competence at integrating CDK4/6 inhibitors into practice to improve clinical outcomes in patients with HR-positive/HER2-negative early breast cancer.

Target Audience
This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the care of patients with HR-positive/HER2-negative early breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Collaborate with multidisciplinary colleagues to identify each patient with HR-positive/HER2-negative EBC who is eligible for CDK4/6 inhibitor treatment

  • Recommend the optimal CDK4/6 inhibitor treatment for each patient with HR-positive/HER2-negative EBC in alignment with NCCN Guidelines, high-level evidence, and expert-recommended best practices

  • Support open and frequent patient-clinician communication to enable effective counseling on the benefits vs potential risks of adjuvant CDK4/6 inhibitor treatment, reporting of patient-felt toxicities, and screening for barriers to adherence/persistence

  • Implement proactive toxicity monitoring, dose modification, and supportive care to enable patient adherence and persistence to CDK4/6 inhibitor treatment for HR-positive/HER2-negative EBC

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.0 contact hour. This program offers 1.0 pharmacotherapeutic contact hour for nurses.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-26-029-L01-P.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN’s Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by

Provided by National Comprehensive Cancer Network in collaboration with Decera Clinical Education.

NCCN

Supporters

This activity is supported by educational grants from Lilly and Novartis.

Lilly

Novartis

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191